Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer
- Conditions
- Colorectal NeoplasmsStomach NeoplasmEsophageal Neoplasms
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 2
- Registration Number
- NCT03153280
- Locations
- 🇮🇪
St James's Hospital, Dublin 8, Ireland
🇮🇪Cork University Hospital, Cork, Ireland
Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 32
- Registration Number
- NCT03146377
- Locations
- 🇭🇰
Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: CyclophosphamideDrug: OxaliplatinDrug: CapecitabineDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-paclitaxelBiological: bevacizumabBiological: avelumabBiological: ALT-803Biological: aNK for InfusionBiological: ETBX-011Biological: GI-4000
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03136406
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Advanced or Metastatic Biliary Tract Cancer
- Interventions
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- ASLAN Pharmaceuticals
- Registration Number
- NCT03129074
Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
- Conditions
- Stage IVA Intrahepatic CholangiocarcinomaStage IVB Intrahepatic CholangiocarcinomaBile Duct AdenocarcinomaStage III Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT03117855
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 54
- Registration Number
- NCT03117972
- Locations
- 🇫🇷
CHU de REIMS, Hôpital Robert Debré, Reims, France
🇫🇷Centre Hospitalier Universitaire de Besançon, Besançon, France
🇫🇷Centre Hospitalier de Boulogne sur Mer, Boulogne-sur-Mer, France
Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Target Recruit Count
- 170
- Registration Number
- NCT03114085
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
- Conditions
- Liver CancerBiliary Tract NeoplasmsCholangiocarcinomaBile Duct CancerGallbladder Cancer
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT03111732
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT03093870
- Locations
- 🇺🇸
Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇯🇵There are 7 sites in different cities in Japan, Chiba, Japan
Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 351
- Registration Number
- NCT03084939
- Locations
- 🇨🇳
Beijing Hospital, Beijing City, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Changzhou First People's Hospital, Changzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.